Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
A recent workshop brought together global leaders in diabetes to assess existing approaches to disease heterogeneity and to identify research gaps, with a goal of achieving precision diabetology for all patients globally.
The European Association for the Study of Obesity presents a new framework for the diagnosis, staging and management of obesity in adults to better align with the concept of obesity as an adiposity-based chronic disease.
A randomized trial shows that a low-cost, accessible, walking-based intervention reduced low-back-pain recurrence, and could offer a scalable approach to tackling this common condition.
Alzheimer’s disease can be treated by targeting amyloid-β plaques and diagnosed in vivo by biomarkers, prompting the revision of criteria for the diagnosis and staging of this disease.
A phase 3 trial establishes 177Lu-dotatate plus long-acting octreotide as a new first-line treatment for patients with high-grade gastroenteropancreatic neuroendocrine tumors.
Fortunate Machingura heads CeSHHAR Zimbabwe’s Climate, Environment, and Health Department and is also a lecturer at the Liverpool School of Tropical Medicine. She describes her pivot from HIV research to another crucial challenge facing Africa: climate change.
For precision genetic medicines to fulfill their potential as treatments for ultra-rare diseases, fresh approaches to academic–industry partnerships and data sharing are needed, together with regulatory change and adaptation of reimbursement models.
The prospect of genomic screening in newborns attracts both hype and criticism, but carefully designed, large-scale, prospective research studies are the only way to generate the data needed for its rigorous evaluation.
The phase 3 NADINA trial showed impressive responses to neoadjuvant nivolumab plus ipilimumab relative to adjuvant nivolumab (the current best practice), revealing a new standard of care for patients with stage III melanoma.
Juliane Fonseca de Oliveira is a mathematician at CIDACS in Salvador, Bahia, Brazil. She describes her part in building an epidemiological model to analyze the diverse populations within the 100 Million Brazilians Cohort.
African nations now lead the world in the rollout of pre-exposure prophylaxis against HIV — in part thanks to social media influencers who promote use of the life-saving drug.
The largest genome-wide association study of its kind has identified new markers for risk prediction in women of African ancestry — helping to bridge disparities in clinical genomics.